316 related articles for article (PubMed ID: 25814163)
1. Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009-13).
Sader HS; Farrell DJ; Flamm RK; Jones RN
J Antimicrob Chemother; 2015 Jul; 70(7):2053-6. PubMed ID: 25814163
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in US Medical Centers.
Sader HS; Farrell DJ; Flamm RK; Jones RN
Surg Infect (Larchmt); 2016 Aug; 17(4):443-7. PubMed ID: 26990170
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
Sader HS; Flamm RK; Jones RN
Antimicrob Agents Chemother; 2013 Jul; 57(7):3178-81. PubMed ID: 23629712
[TBL] [Abstract][Full Text] [Related]
4. Activity analyses of staphylococcal isolates from pediatric, adult, and elderly patients: AWARE Ceftaroline Surveillance Program.
Sader HS; Flamm RK; Farrell DJ; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S181-6. PubMed ID: 22903950
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Sader HS; Flamm RK; Jones RN
Diagn Microbiol Infect Dis; 2013 May; 76(1):61-8. PubMed ID: 23535208
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections.
Isnard C; Dhalluin A; Malandain D; Bruey Q; Auzou M; Michon J; Giard JC; Guérin F; Cattoir V
J Glob Antimicrob Resist; 2018 Jun; 13():221-225. PubMed ID: 29421316
[TBL] [Abstract][Full Text] [Related]
7. Ceftaroline activity against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2009-2011).
Pfaller MA; Flamm RK; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2014 Apr; 78(4):422-8. PubMed ID: 24445158
[TBL] [Abstract][Full Text] [Related]
8. Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: results from the AWARE Program, 2009-2011.
Flamm RK; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2014 Apr; 78(4):437-42. PubMed ID: 24582578
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections.
Hodille E; Delouere L; Bouveyron C; Meugnier H; Bes M; Tristan A; Laurent F; Vandenesch F; Lina G; Dumitrescu O
Med Mal Infect; 2017 Mar; 47(2):152-157. PubMed ID: 27856079
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012).
Flamm RK; Farrell DJ; Sader HS; Jones RN
Diagn Microbiol Infect Dis; 2014 Apr; 78(4):449-56. PubMed ID: 24529941
[TBL] [Abstract][Full Text] [Related]
11. Nationwide surveillance of resistance rates of Staphylococcus aureus clinical isolates from Greek hospitals, 2012-2013.
Souli M; Karaiskos I; Galani L; Maraki S; Perivolioti E; Argyropoulou A; Charissiadou A; Zachariadou L; Tsiplakou S; Papaioannou V; Tsorlini H; Katsifa H; Baka V; Pantazi P; Paschali A; Kyratsa A; Trikka-Graphakos E; Giannopoulou P; Vogiatzakis E; Moraitou H; Papadogeorgaki H; Avgerinou H; Panagea T; Pantazatou A; Petinaki E; Stamatopoulou G; Toutouza M; Karatzoglou I; Kontopoulou K; Orfanidou M; Karantani I; Fytas P; Tzanetou K; Platsouka E; Kazila P; Chli A; Statiri N; Giamarellou H
Infect Dis (Lond); 2016 Apr; 48(4):287-292. PubMed ID: 26635179
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: a review of published studies and the AWARE Surveillance Program (2008-2010).
Farrell DJ; Castanheira M; Mendes RE; Sader HS; Jones RN
Clin Infect Dis; 2012 Sep; 55 Suppl 3():S206-14. PubMed ID: 22903953
[TBL] [Abstract][Full Text] [Related]
13. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
[TBL] [Abstract][Full Text] [Related]
14. Activity of ceftaroline and epidemiologic trends in Staphylococcus aureus isolates collected from 43 medical centers in the United States in 2009.
Richter SS; Heilmann KP; Dohrn CL; Riahi F; Costello AJ; Kroeger JS; Biek D; Critchley IA; Diekema DJ; Doern GV
Antimicrob Agents Chemother; 2011 Sep; 55(9):4154-60. PubMed ID: 21709080
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals.
Housman ST; Sutherland CA; Nicolau DP
Int J Antimicrob Agents; 2014 Sep; 44(3):235-41. PubMed ID: 25052866
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial activity of ceftaroline and comparator agents tested against organisms isolated from patients with community-acquired bacterial pneumonia in Europe, Asia, and Latin America.
Sader HS; Flamm RK; Streit JM; Carvalhaes CG; Mendes RE
Int J Infect Dis; 2018 Dec; 77():82-86. PubMed ID: 30315990
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative Staphylococcus causing infection in US hospitals.
Sader HS; Farrell DJ; Flamm RK; Streit JM; Mendes RE; Jones RN
Diagn Microbiol Infect Dis; 2016 May; 85(1):80-4. PubMed ID: 26971182
[TBL] [Abstract][Full Text] [Related]
18. Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010-2019).
Sader HS; Carvalhaes CG; Mendes RE
Int J Infect Dis; 2021 Jan; 102():524-528. PubMed ID: 33207274
[TBL] [Abstract][Full Text] [Related]
19. Ceftaroline activity tested against bacterial isolates from pediatric patients: results from the assessing worldwide antimicrobial resistance and evaluation program for the United States (2011-2012).
Sader HS; Mendes RE; Farrell DJ; Flamm RK; Jones RN
Pediatr Infect Dis J; 2014 Aug; 33(8):837-42. PubMed ID: 25222304
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).
Huband MD; Castanheira M; Farrell DJ; Flamm RK; Jones RN; Sader HS; Mendes RE
Int J Antimicrob Agents; 2016 Jun; 47(6):495-9. PubMed ID: 27211209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
